[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR077080A1 - Compuestos de 2,3-dihidro-1h-indeno - Google Patents

Compuestos de 2,3-dihidro-1h-indeno

Info

Publication number
AR077080A1
AR077080A1 ARP100102082A ARP100102082A AR077080A1 AR 077080 A1 AR077080 A1 AR 077080A1 AR P100102082 A ARP100102082 A AR P100102082A AR P100102082 A ARP100102082 A AR P100102082A AR 077080 A1 AR077080 A1 AR 077080A1
Authority
AR
Argentina
Prior art keywords
compounds
dihidro
indeno
cycloalkyl
alkyl
Prior art date
Application number
ARP100102082A
Other languages
English (en)
Inventor
Alexander Hird
Vibha Oza
Jamel Carlos Saeh
Li Sha
Brian Aquila
Edward Hennessy
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR077080A1 publication Critical patent/AR077080A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos de 2,3-dihidro-1H-indeno, métodos para obtener dichos compuestos y composiciones farmacéuticas que los contienen. Los compuestos que se describen inhiben a las proteínas IAP (proteínas inhibidoras de la apoptosis) y se pueden utilizar en el tratamiento de diversos tipos de cáncer. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1) donde R1 y R2 son, independientemente, H o alquilo C1-6; R3 es H o cicloalquilo C3-8; R4 es -OC-alquil C3-10-O-, -OC-alquenil C3-10-O- u -OC-alquinil C3-10-O-, R5 es H o cicloalquilo C3-8; y R6 y R7 son, independientemente, H o alquilo C1-6; o una sal del mismo.
ARP100102082A 2009-06-12 2010-06-11 Compuestos de 2,3-dihidro-1h-indeno AR077080A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18659409P 2009-06-12 2009-06-12

Publications (1)

Publication Number Publication Date
AR077080A1 true AR077080A1 (es) 2011-07-27

Family

ID=42630911

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102082A AR077080A1 (es) 2009-06-12 2010-06-11 Compuestos de 2,3-dihidro-1h-indeno

Country Status (11)

Country Link
US (1) US20100317593A1 (es)
EP (1) EP2440549A1 (es)
JP (1) JP2012529482A (es)
KR (1) KR20120046162A (es)
CN (1) CN102459238A (es)
AR (1) AR077080A1 (es)
AU (1) AU2010258437A1 (es)
CA (1) CA2765150A1 (es)
TW (1) TW201103536A (es)
UY (1) UY32704A (es)
WO (1) WO2010142994A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US11639354B2 (en) 2018-07-31 2023-05-02 Fimecs, Inc. Heterocyclic compound
WO2020046941A1 (en) * 2018-08-28 2020-03-05 Arbutus Biopharma Corporation Crystalline forms of substituted dihydroindene-4-carboxamide compounds and methods of preparing and using same
WO2020109328A1 (en) 2018-11-26 2020-06-04 Debiopharm International S.A. Combination treatment of hiv infections
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
MX2021006156A (es) * 2018-11-30 2021-09-08 Glaxosmithkline Ip Dev Ltd Compuestos utiles en la terapia para el vih.
CN113573707A (zh) 2019-01-17 2021-10-29 德彪药业国际股份公司 用于治疗癌症的组合产品
EP4006037A4 (en) 2019-07-31 2023-12-13 Fimecs, Inc. HETEROCYCLIC COMPOUND
MX2022003628A (es) 2019-09-25 2022-07-21 Debiopharm Int Sa Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.
AU2021211871A1 (en) 2020-01-20 2022-09-08 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2023230432A1 (en) 2022-05-23 2023-11-30 Inhibrx, Inc. Dr5 agonist and iap antagonist combination therapy

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2078258T3 (es) * 1989-04-28 1995-12-16 Sclavo Spa Mutantes de toxina pertussica, cepas de bordetella capaces de producir tales mutantes y su uso en el desarrollo de vacunas antipertussicas.
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US6187557B1 (en) * 1995-08-08 2001-02-13 Tularik Inc. c-IAP1 and c-IAP2: inhibitors of apoptosis
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ES2194181T3 (es) 1996-02-13 2003-11-16 Astrazeneca Ab Derivados de quinazolina como inhibidores de vegf.
CA2244897C (en) 1996-03-05 2006-04-11 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6242569B1 (en) * 1997-02-05 2001-06-05 Tularik, Inc. Regulators of apoptosis
US6162965A (en) * 1997-06-02 2000-12-19 Novartis Ag Plant transformation methods
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6162913A (en) * 1998-07-15 2000-12-19 Bristol-Myers Squibb Co. Preparation of [4S-(4α,7α,10aβ)]-4-amino-octahydro-5-oxo-7H-pyrido[2,1 -b] [1,3]thiazepine-7-carboxylic acid, methyl ester and salts thereof via novel disulfides
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SI1553097T1 (sl) 1999-02-10 2010-12-31 Astrazeneca Ab Kinazolinski derivati kot inhibitorji angiogeneze in intermediati za to
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
US20040171554A1 (en) * 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
US20080199439A1 (en) * 2003-02-12 2008-08-21 Mclendon George L IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods
JP4674231B2 (ja) * 2004-03-01 2011-04-20 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ２量体小分子アポトーシス増強剤
WO2005092326A1 (en) * 2004-03-22 2005-10-06 The Regents Of The University Of Michigan Small molecule antagonists of xiap family proteins
WO2006014361A1 (en) * 2004-07-02 2006-02-09 Genentech, Inc. Inhibitors of iap
EP2457895A1 (en) * 2004-07-12 2012-05-30 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
EP1773766B1 (en) * 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Iap binding compounds
CN103083644B (zh) * 2005-02-25 2014-05-28 泰特拉洛吉克药业公司 Iap二聚体抑制剂
DE102005017116A1 (de) * 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
CA2607940C (en) * 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
MX2007015419A (es) * 2005-06-08 2008-02-21 Novartis Ag Compuestos organicos.
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
JP2009512719A (ja) * 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド Ｉａｐｂｉｒドメイン結合化合物
CA2632256A1 (en) * 2005-12-20 2007-07-05 Novartis Ag Combination of an iap-inhibitor and a taxane7
TWI543988B (zh) * 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
US20090043099A1 (en) * 2006-03-17 2009-02-12 The Burnham Institute Methods and compositions for derepression of IAP-inhibited caspase
US8202902B2 (en) * 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
SG10201407457UA (en) * 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
KR20090041391A (ko) * 2006-07-24 2009-04-28 테트랄로직 파마슈티칼스 이량체성 ｉａｐ 길항제
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2049524A2 (en) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap inhibitors
US20100144650A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
KR20090065548A (ko) * 2006-10-12 2009-06-22 노파르티스 아게 Ｉａｐ 억제제로서의 피롤리딘 유도체
JP2010511057A (ja) * 2006-11-28 2010-04-08 ノバルティス アーゲー 急性骨髄性白血病の処置のためのｉａｐ阻害剤の使用
PT2089024E (pt) * 2006-11-28 2011-08-31 Novartis Ag Combinação de inibidores de iap e inibidores de flt3
AU2007332862A1 (en) * 2006-12-07 2008-06-19 Novartis Ag Organic compounds
ES2370536T3 (es) * 2006-12-07 2011-12-19 Novartis Ag 6-oxo-1,6-dihidropirimidín-2-ils en el tratamiento de enfermedades proliferativas.
US20110008802A1 (en) * 2007-05-07 2011-01-13 Tetralogic Pharmaceuticals Corp. TNFalpha GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS
US20100203012A1 (en) * 2007-05-30 2010-08-12 Aegera Therapeutics, Inc. Iap bir domain binding compounds
US20110117081A1 (en) * 2008-05-05 2011-05-19 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
CA2728933A1 (en) * 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
US20110177060A1 (en) * 2008-09-19 2011-07-21 Aegera Therapeutics, Inc. Iap bir domain binding compounds
US8088890B2 (en) * 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US8440693B2 (en) * 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
UY33236A (es) * 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap

Also Published As

Publication number Publication date
TW201103536A (en) 2011-02-01
EP2440549A1 (en) 2012-04-18
WO2010142994A1 (en) 2010-12-16
CN102459238A (zh) 2012-05-16
CA2765150A1 (en) 2010-12-16
KR20120046162A (ko) 2012-05-09
US20100317593A1 (en) 2010-12-16
AU2010258437A1 (en) 2012-01-12
UY32704A (es) 2011-01-31
JP2012529482A (ja) 2012-11-22

Similar Documents

Publication Publication Date Title
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
SV2016005229A (es) Inhibidores de syk
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY32730A (es) Inhibidores de cyp17
UY36285A (es) Compuestos que inhiben la proteína mcl-1
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
AR094966A1 (es) Composiciones farmacéuticas para el tratamiento de infecciones hcv
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
DOP2014000178A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
CL2020001244A1 (es) Inhibidores de inmunoproteasoma.
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
CO2018010787A2 (es) Compuesto de griseofulvina
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
AR095097A1 (es) Compuestos de fenoxietoxi
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
PE20150674A1 (es) Azaheterociclos como inhibidores de bir2 y/o bir3

Legal Events

Date Code Title Description
FB Suspension of granting procedure